MCID: PRM042
MIFTS: 58

Primary Effusion Lymphoma

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Primary Effusion Lymphoma

MalaCards integrated aliases for Primary Effusion Lymphoma:

Name: Primary Effusion Lymphoma 53 59 73
Pel 53 59
Body Cavity-Based Lymphoma 59
Lymphoma, Aids-Related 73
Aids-Related Lymphoma 53
Lymphoma Aids-Related 55

Characteristics:

Orphanet epidemiological data:

59
primary effusion lymphoma
Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 59 ORPHA48686
MESH via Orphanet 45 D054685
UMLS via Orphanet 74 C1292753
ICD10 via Orphanet 34 C83.8

Summaries for Primary Effusion Lymphoma

MalaCards based summary : Primary Effusion Lymphoma, also known as pel, is related to plasmablastic lymphoma and human herpesvirus 8. An important gene associated with Primary Effusion Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs rituximab and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and liver, and related phenotypes are pericardial effusion and abdominal pain

Wikipedia : 76 Primary effusion lymphoma (PEL) is a B-cell lymphoma, presenting with a malignant effusion without a... more...

Related Diseases for Primary Effusion Lymphoma

Diseases related to Primary Effusion Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 plasmablastic lymphoma 32.7 BCL6 MYC
2 human herpesvirus 8 32.6 BCL6 IL6
3 kaposi sarcoma 31.2 AKT1 IL6 MYC VEGFA
4 multicentric castleman disease 30.4 BCL6 IL6
5 richter's syndrome 30.1 IRF4 MYC
6 diffuse large b-cell lymphoma 30.0 BCL6 IRF4 MYC
7 follicular lymphoma 29.7 BCL6 IRF4 MYC
8 b-cell lymphomas 28.9 BCL6 CASP3 IRF4 MYC TCL1A
9 hepatocellular carcinoma 27.5 AKT1 CASP3 IL6 MYC VEGFA
10 myeloma, multiple 27.2 AKT1 CASP3 IL6 IRF4 MYC VEGFA
11 lymphoma aids related 11.6
12 lymphoma 11.0
13 pelger-huet anomaly 10.9
14 sarcoma 10.6
15 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL6 MYC
16 critical limb ischemia 10.6 IL6 VEGFA
17 lymphangiosarcoma 10.5 MYC VEGFA
18 spinal disease 10.5 IL6 VEGFA
19 poems syndrome 10.5 IL6 VEGFA
20 spindle cell sarcoma 10.5 IL6 VEGFA
21 gastric lymphoma 10.4 BCL6 VEGFA
22 primary mediastinal large b-cell lymphoma 10.4 BCL6 IRF4
23 colon lymphoma 10.4 BCL6 IRF4
24 macular retinal edema 10.4 IL6 VEGFA
25 post-transplant lymphoproliferative disease 10.3 IL6 TNFSF10
26 crimean-congo hemorrhagic fever 10.3 CASP3 IL6
27 central retinal vein occlusion 10.3 IL6 VEGFA
28 eales disease 10.3 IL6 VEGFA
29 plasmacytoma 10.2 IL6 IRF4 MYC
30 cowpox 10.2 CASP3 IL6
31 hepatitis 10.2
32 t-cell prolymphocytic leukemia 10.2 MYC TCL1A VEGFA
33 nervous system disease 10.1 CASP3 IL6 VEGFA
34 lymphatic system cancer 10.1 BCL6 MYC
35 hepatitis c 10.1
36 plasma cell neoplasm 10.1 IL6 MYC
37 hepatitis c virus 10.1
38 acquired immunodeficiency syndrome 10.1 BCL6 IL6 MYC
39 liver cirrhosis 10.0
40 peritonitis 10.0
41 castleman disease 10.0
42 endotheliitis 10.0
43 adamantinoma of long bones 10.0 CASP3 MYC TNFSF10 VEGFA
44 hepatitis b 9.9
45 traumatic brain injury 9.9 CASP3 IL6
46 macular degeneration, age-related, 1 9.9 CASP3 CTSD VEGFA
47 autoimmune lymphoproliferative syndrome, type v 9.8
48 cardiac tamponade 9.8
49 pancreas adenocarcinoma 9.8 AKT1 MYC VEGFA
50 pharynx cancer 9.7 AKT1 CASP3 VEGFA

Graphical network of the top 20 diseases related to Primary Effusion Lymphoma:



Diseases related to Primary Effusion Lymphoma

Symptoms & Phenotypes for Primary Effusion Lymphoma

Human phenotypes related to Primary Effusion Lymphoma:

59 32 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pericardial effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0001698
2 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
3 dyspnea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002094
4 pleural effusion 59 32 hallmark (90%) Very frequent (99-80%) HP:0002202
5 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
6 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
7 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
8 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191

MGI Mouse Phenotypes related to Primary Effusion Lymphoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 IRF4 VEGFA MYC IL6 BCL6 CTSD
2 hematopoietic system MP:0005397 10.16 MYC IL6 TNFSF10 VEGFA IRF4 CTSD
3 endocrine/exocrine gland MP:0005379 10.15 MYC IL6 TNFSF10 VEGFA CTSD CASP3
4 cardiovascular system MP:0005385 10.13 VEGFA MYC IL6 TNFSF10 BCL6 CASP3
5 growth/size/body region MP:0005378 10.13 IRF4 VEGFA MYC IL6 CDK2 BCL6
6 homeostasis/metabolism MP:0005376 10.13 VEGFA MYC IL6 TNFSF10 IRF4 BCL6
7 immune system MP:0005387 10.1 MYC IL6 TNFSF10 IRF4 VEGFA CTSD
8 integument MP:0010771 9.91 VEGFA MYC IL6 CDK2 CTSD CASP3
9 mortality/aging MP:0010768 9.91 VEGFA MYC TNFSF10 IL6 CDK2 BCL6
10 liver/biliary system MP:0005370 9.87 VEGFA MYC IL6 TNFSF10 BCL6 AKT1
11 muscle MP:0005369 9.7 VEGFA MYC IL6 BCL6 CASP3 AKT1
12 neoplasm MP:0002006 9.5 MYC IL6 TNFSF10 IRF4 VEGFA AKT1
13 reproductive system MP:0005389 9.23 VEGFA MYC TCL1A IL6 BCL6 CASP3

Drugs & Therapeutics for Primary Effusion Lymphoma

Drugs for Primary Effusion Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
2
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
3
Sulfamethoxazole Approved Phase 2 723-46-6 5329
4
Etoposide Approved Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
6
Doxorubicin Approved, Investigational Phase 2,Phase 1,Not Applicable 23214-92-8 31703
7
Ifosfamide Approved Phase 2 3778-73-2 3690
8
Allopurinol Approved Phase 2,Not Applicable 315-30-0 2094
9
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
10
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
11
Trimethoprim Approved, Vet_approved Phase 2 738-70-5 5578
12
Vincristine Approved, Investigational Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
13
Methotrexate Approved Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
14
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
15
Cytarabine Approved, Investigational Phase 2,Not Applicable 147-94-4 6253
16
Zidovudine Approved Phase 2,Not Applicable 30516-87-1 35370
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
19
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
20
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
21
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
24
Bleomycin Approved, Investigational Phase 2,Not Applicable 11056-06-7 5360373
25
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
26
Fluorouracil Approved Phase 2 51-21-8 3385
27
Bevacizumab Approved, Investigational Phase 2 216974-75-3
28
Valganciclovir Approved, Investigational Phase 2 175865-60-8 64147
29
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
30
Levoleucovorin Approved, Investigational Phase 2,Not Applicable 68538-85-2
31
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
32
Cortisone acetate Approved, Investigational Phase 1, Phase 2 1950-04-4, 50-04-4 5745
33
nivolumab Approved Phase 2 946414-94-4
34
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
35
leucovorin Approved, Nutraceutical Phase 2,Not Applicable 58-05-9 143 6006
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 59-30-3 6037
37
Doxil Approved June 1999 Phase 2,Phase 1,Not Applicable 31703
38 Prednisolone acetate Phase 2
39
Isophosphamide mustard Phase 2 0
40 Alkylating Agents Phase 2,Phase 1,Not Applicable
41 glucocorticoids Phase 2,Phase 1,Not Applicable
42 Renal Agents Phase 2
43 Methylprednisolone acetate Phase 2
44 Methylprednisolone Hemisuccinate Phase 2
45 Adjuvants, Immunologic Phase 2,Phase 1
46 Reverse Transcriptase Inhibitors Phase 2,Not Applicable
47 Folic Acid Antagonists Phase 2,Not Applicable
48 Ganciclovir triphosphate Phase 2
49 Gastrointestinal Agents Phase 2,Not Applicable
50 Neuroprotective Agents Phase 2

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma Completed NCT00217503 Phase 2 bortezomib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ganciclovir;valganciclovir;zidovudine
2 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002524 Phase 2 Cisplatin;Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride (DOX);Etoposide;Fluorouracil;Ifosfamide;Leucovorin calcium;Methotrexate;Methylprednisolone;Pentamidine;Prednisone;Trimethoprim-Sulfamethoxazole;Vincristine Sulfate;Zidovudine (AZT)
3 SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00002571 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;prednisone;trimethoprim-sulfamethoxazole;vincristine sulfate;Intrathecal cytarabine
4 Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma Completed NCT00005824 Phase 2 busulfan;cyclophosphamide
5 EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma Completed NCT00001563 Phase 2 EPOCH
6 Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed NCT00003388 Phase 2 cyclophosphamide;cytarabine;methotrexate;pegylated liposomal doxorubicin hydrochloride;prednisone;vincristine sulfate
7 A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL Completed NCT00799136 Phase 2 R-EPOCH and cART
8 High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT Completed NCT00858793 Phase 1, Phase 2
9 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease Completed NCT00003114 Phase 2 cyclophosphamide;etoposide;lomustine;procarbazine hydrochloride
10 Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Recruiting NCT02911142 Phase 1, Phase 2 Lenalidomide;Rituximab;Prednisone;Etopside;Doxorubicin;Vincristine;Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
11 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
12 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma Recruiting NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;cyclophosphamide;procarbazine hydrochloride
13 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
14 Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma Terminated NCT00126243 Phase 2 rituximab;CHOP
15 Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas Terminated NCT00183976 Phase 2 Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
16 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
17 Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma Withdrawn NCT00024128 Phase 2 cyclophosphamide;cyclosporine
18 Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma Withdrawn NCT00310128 Phase 2 cisplatin;cytarabine;etoposide;methylprednisolone;rituximab;yttrium Y 90 ibritumomab tiuxetan
19 Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Recruiting NCT03220022 Phase 1 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ibrutinib;Prednisone;Vincristine Sulfate
20 Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies Recruiting NCT02924402 Phase 1
21 Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma Active, not recruiting NCT00569985 Phase 1 carmustine;cyclophosphamide;etoposide
22 Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting NCT01961063 Phase 1 busulfan
23 Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting NCT02337985 Phase 1 Prednisone;Etoposide;Doxorubicin Hydrochloride;Vincristine Sulfate;Cyclophosphamide
24 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
25 Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States Completed NCT00026728
26 Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members Completed NCT00000703 Not Applicable Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Zidovudine;Dexamethasone
27 Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma Recruiting NCT02823327
28 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
29 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Recruiting NCT02652715 Not Applicable
30 124I-FIAU Imaging in EBV and KSHV Associated Cancers Recruiting NCT00982449 Early Phase 1
31 Prospective Study of Lymphoproliferative Diseases Withdrawn NCT01704742
32 Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Withdrawn NCT01769911 Not Applicable carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine
33 Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer Withdrawn NCT00499668 Not Applicable aprepitant;ondansetron hydrochloride

Search NIH Clinical Center for Primary Effusion Lymphoma

Genetic Tests for Primary Effusion Lymphoma

Anatomical Context for Primary Effusion Lymphoma

MalaCards organs/tissues related to Primary Effusion Lymphoma:

41
B Cells, T Cells, Liver, Endothelial, Heart, Brain, Testis

Publications for Primary Effusion Lymphoma

Articles related to Primary Effusion Lymphoma:

(show top 50) (show all 422)
# Title Authors Year
1
KSHV/HHV8-Associated Extracavitary Primary Effusion Lymphoma Presenting as Multiple Lymphomatous Polyposis. ( 29505765 )
2018
2
Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation. ( 29207179 )
2018
3
MALT1 protease activity in primary effusion lymphoma. ( 29560084 )
2018
4
The utility of multiparametric flow cytometry in the detection of primary effusion lymphoma (PEL). ( 29669178 )
2018
5
Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. ( 29739902 )
2018
6
A case of Epstein-Barr virus-negative human immunodeficiency virus-related primary effusion lymphoma. ( 29454632 )
2018
7
Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models. ( 29207182 )
2018
8
Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient. ( 29619259 )
2018
9
CK1I+ and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. ( 29954751 )
2018
10
Expression and subcellular localization of the KSHV K15P protein during latency and lytic reactivation in primary effusion lymphoma cells. ( 28835496 )
2017
11
Correction for Cousins et al., "Human Herpesvirus 8 Viral Interleukin-6 Signaling through gp130 Promotes Virus Replication in Primary Effusion Lymphoma and Endothelial Cells". ( 29138334 )
2017
12
HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. ( 28705937 )
2017
13
Diversity of human herpesvirus 8 genotypes in patients with AIDS and non-AIDS associated Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in Argentina. ( 28617968 )
2017
14
Post-transplant Lymphoproliferative Disorder Presented in a Form of Primary Effusion Lymphoma with t (8; 14). ( 28667038 )
2017
15
SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells. ( 28393364 )
2017
16
Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. ( 28922425 )
2017
17
Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma presenting with cardiac tamponade: A case report. ( 29068981 )
2017
18
Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. ( 28092744 )
2017
19
Primary effusion lymphoma in Taiwan shows two distinctive clinicopathological subtypes with rare human immunodeficiency virus association. ( 29206290 )
2017
20
1, 25(OH)2 D3 Induces Reactivation and Death of Kaposi's Sarcoma-Associated Herpesvirus of Primary Effusion Lymphoma cells. ( 28963501 )
2017
21
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. ( 29021516 )
2017
22
Up-regulation of tumor suppressor genes by exogenous dhC16-Cer contributes to its anti-cancer activity in primary effusion lymphoma. ( 28146424 )
2017
23
Correction for Cousins and Nicholas, "Role of Human Herpesvirus 8 Interleukin-6-Activated gp130 Signal Transducer in Primary Effusion Lymphoma Cell Growth and Viability". ( 29191994 )
2017
24
Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma. ( 28653223 )
2017
25
Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. ( 28468596 )
2017
26
Ribonucleotide reductase represents a novel therapeutic target in primary effusion lymphoma. ( 28459467 )
2017
27
An intrasinusoidal extracavitary variant of primary effusion lymphoma. ( 28798059 )
2017
28
InA vitro and inA vivo anti-primary effusion lymphoma activities of fucoidan extracted from Cladosiphon okamuranus Tokida. ( 29048633 )
2017
29
Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge. ( 28880367 )
2017
30
Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy. ( 28580733 )
2017
31
Rapidly progressive intravascular primary effusion lymphoma in an HIV-positive renal transplant recipient. ( 28815752 )
2017
32
Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. ( 28847988 )
2017
33
Primary effusion lymphoma: current concepts and management. ( 28399009 )
2017
34
A unique case of primary effusion lymphoma-like lymphoma showing disappearance and recurrence of the body cavity effusion. ( 29263988 )
2017
35
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. ( 28432410 )
2017
36
Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma. ( 28481873 )
2017
37
Lymphoproliferative disorders with concurrent HHV8 and EBV infection: beyond primary effusion lymphoma and germinotropic lymphoproliferative disorder. ( 29105119 )
2017
38
Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. ( 28084853 )
2017
39
YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma. ( 28396094 )
2017
40
Epigallocatechin-3-Gallate Suppresses Human Herpesvirus 8 Replication and Induces ROS Leading to Apoptosis and Autophagy in Primary Effusion Lymphoma Cells. ( 29267216 )
2017
41
Primary effusion lymphoma-like lymphoma with a T cell phenotype. ( 29199356 )
2017
42
Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma. ( 28407694 )
2017
43
A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma. ( 29279707 )
2017
44
Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience. ( 27521315 )
2016
45
Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. ( 27414752 )
2016
46
Triptolide inhibits transcription of hTERT through down-regulation of transcription factor specificity protein 1 in primary effusion lymphoma cells. ( 26631963 )
2016
47
Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma (PEL-LL) in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. ( 27283030 )
2016
48
Diagnostic pitfall: primary effusion lymphoma with rare cytokeratin immunoreactivity. ( 28092872 )
2016
49
Establishing and characterizing a new primary effusion lymphoma cell line harboring Kaposi's sarcoma-associated herpesvirus. ( 27536332 )
2016
50
Primary Effusion Lymphoma (PEL)-Like Lymphoma in a Child With Congenital Immunodeficiency. ( 27186682 )
2016

Variations for Primary Effusion Lymphoma

Copy number variations for Primary Effusion Lymphoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 25103 1 184000000 197500000 Gain primary effusion lymphomas
2 189792 4 78400000 172200000 Gain primary effusion lymphomas
3 239813 8 41800000 84900000 Gain primary effusion lymphomas
4 262574 X 37500000 98200000 Gain primary effusion lymphomas

Expression for Primary Effusion Lymphoma

Search GEO for disease gene expression data for Primary Effusion Lymphoma.

Pathways for Primary Effusion Lymphoma

Pathways related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 AKT1 BCL6 CASP3 CTSD IL6 IRF4
2
Show member pathways
13.74 AKT1 CASP3 CDK2 IL6 MYC TNFSF10
3
Show member pathways
13.19 AKT1 BCL6 CASP3 IL6 IRF4 MYC
4
Show member pathways
12.79 AKT1 CASP3 IL6 TNFSF10
5
Show member pathways
12.79 AKT1 CASP3 CDK2 MYC VEGFA
6
Show member pathways
12.71 AKT1 CASP3 CDK2 IL6 TNFSF10
7
Show member pathways
12.69 AKT1 CASP3 CDK2 IL6 MYC TCL1A
8
Show member pathways
12.68 AKT1 CDK2 IL6 VEGFA
9 12.68 AKT1 CASP3 CDK2 IL6 MYC VEGFA
10 12.67 AKT1 CASP3 MYC VEGFA
11
Show member pathways
12.64 AKT1 CASP3 CTSD IRF4 MYC TNFSF10
12
Show member pathways
12.58 AKT1 CASP3 TNFSF10 VEGFA
13
Show member pathways
12.57 AKT1 IL6 IRF4 MYC
14
Show member pathways
12.42 AKT1 CASP3 CTSD MYC
15
Show member pathways
12.32 AKT1 BCL6 IRF4 MYC
16
Show member pathways
12.25 AKT1 CASP3 CDK2 IL6 MYC VEGFA
17 12.23 AKT1 CASP3 MYC VEGFA
18
Show member pathways
12.21 AKT1 CASP3 TNFSF10
19 12.21 AKT1 CDK2 MYC
20 12.17 BCL6 IL6 MYC
21
Show member pathways
12.17 AKT1 CASP3 CDK2 TNFSF10
22 12.16 CASP3 CTSD MYC TNFSF10
23 12.13 AKT1 CASP3 CTSD IL6
24 12.1 CASP3 IL6 VEGFA
25
Show member pathways
12.1 AKT1 CASP3 CDK2 VEGFA
26 12.09 AKT1 CASP3 CDK2 MYC
27
Show member pathways
12.06 AKT1 CASP3 MYC
28 12.06 AKT1 CDK2 IL6 MYC
29 12.05 AKT1 CASP3 IL6 MYC VEGFA
30
Show member pathways
12 AKT1 CDK2 MYC
31 12 IL6 MYC VEGFA
32
Show member pathways
12 AKT1 IL6 MYC TNFSF10
33 11.99 AKT1 CASP3 CDK2 MYC VEGFA
34
Show member pathways
11.96 AKT1 CASP3 CTSD
35 11.92 AKT1 BCL6 MYC
36 11.9 AKT1 CDK2 MYC
37 11.9 CASP3 CDK2 IL6 MYC
38 11.89 AKT1 CASP3 IL6
39 11.85 AKT1 IL6 VEGFA
40 11.81 AKT1 CASP3 IL6 VEGFA
41
Show member pathways
11.78 AKT1 IL6 MYC
42 11.76 AKT1 CASP3 CDK2 MYC
43 11.72 AKT1 CDK2 MYC
44
Show member pathways
11.69 AKT1 BCL6 CDK2 IL6 TNFSF10
45 11.67 AKT1 CDK2 MYC
46 11.64 AKT1 CASP3 IL6
47 11.63 AKT1 BCL6 IRF4
48 11.58 AKT1 CASP3 VEGFA
49 11.47 CDK2 MYC VEGFA
50 11.47 AKT1 BCL6 CDK2

GO Terms for Primary Effusion Lymphoma

Biological processes related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 AKT1 IL6 IRF4 MYC VEGFA
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 AKT1 CDK2 IL6 IRF4 MYC
3 positive regulation of gene expression GO:0010628 9.85 AKT1 IL6 MYC VEGFA
4 cellular response to DNA damage stimulus GO:0006974 9.8 AKT1 BCL6 CASP3 CDK2 MYC
5 positive regulation of apoptotic process GO:0043065 9.77 AKT1 BCL6 CASP3 IL6 TNFSF10
6 positive regulation of cell proliferation GO:0008284 9.73 AKT1 CDK2 IL6 MYC TCL1A VEGFA
7 cellular response to hypoxia GO:0071456 9.71 AKT1 MYC VEGFA
8 response to organic substance GO:0010033 9.7 AKT1 CASP3 CDK2
9 cellular response to organic cyclic compound GO:0071407 9.67 AKT1 CASP3 MYC
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.62 AKT1 IL6 TCL1A VEGFA
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.61 AKT1 IL6 MYC
12 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.6 AKT1 VEGFA
13 positive regulation of DNA binding GO:0043388 9.59 IRF4 MYC
14 protein import into nucleus, translocation GO:0000060 9.58 AKT1 BCL6
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.58 MYC VEGFA
16 endocrine pancreas development GO:0031018 9.57 AKT1 IL6
17 positive regulation of cellular component movement GO:0051272 9.51 BCL6 VEGFA
18 negative regulation of apoptotic process GO:0043066 9.5 AKT1 BCL6 CASP3 IL6 MYC TCL1A
19 T-helper 17 cell lineage commitment GO:0072540 9.46 IL6 IRF4
20 positive regulation of mitochondrial membrane potential GO:0010918 9.33 AKT1 MYC TCL1A
21 cytokine-mediated signaling pathway GO:0019221 9.17 AKT1 BCL6 CASP3 IL6 IRF4 MYC

Molecular functions related to Primary Effusion Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.9 AKT1 BCL6 CASP3 CDK2 CTSD IL6
2 identical protein binding GO:0042802 9.35 AKT1 BCL6 TCL1A TNFSF10 VEGFA
3 aspartic-type endopeptidase activity GO:0004190 8.62 CASP3 CTSD

Sources for Primary Effusion Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....